The company is focusing on expanding its drug pipeline, particularly in infectious diseases, to offset declining sales of top drugs and vaccines as demand slows and competition increases, and meet its long-term sales target.

GSK said it was well positioned to weather any financial impact from tariffs, and its outlook had factored in levies implemented so far and expected tariffs on European goods.

The EU-US trade deal announced over the weekend will result in a 15% tariff on most goods, including pharmaceuticals, shipped from the region.

GSK has forecast 2025 revenue to increase between 3% and 5%, with core profit growth per share of 6% to 8%.

“GSK’s strong momentum in 2025 continues with another quarter of excellent performance driven mainly by specialty medicines, our largest business, with double-digit sales growth in respiratory, immunology & inflammation, oncology and HIV,” CEO Emma Walmsley said in a statement.

Overall, turnover rose 6% to nearly £8 billion (US$10.68 billion) on constant currency rates, GSK said, while adjusted earnings stood at 46.5 pence per share for Q2.

Analysts expected earnings of 42.8 pence per share on revenue of £7.80 billion, according to a company-compiled consensus.